Literature DB >> 28616337

Strategies to prevent aortic complications in Marfan syndrome.

Lucio Sartor1, Alberto Forteza1,2.   

Abstract

Entities:  

Year:  2017        PMID： 28616337      PMCID： PMC5462720          DOI： 10.21037/jtd.2017.04.69

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  24 in total

1.  Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome.

Authors:  Anji T Yetman; Renee A Bornemeier; Brian W McCrindle
Journal:  Am J Cardiol       Date:  2005-05-01       Impact factor: 2.778

2.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene.

Authors:  H C Dietz; G R Cutting; R E Pyeritz; C L Maslen; L Y Sakai; G M Corson; E G Puffenberger; A Hamosh; E J Nanthakumar; S M Curristin
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

3.  Marfan Sartan: a randomized, double-blind, placebo-controlled trial.

Authors:  Olivier Milleron; Florence Arnoult; Jacques Ropers; Philippe Aegerter; Delphine Detaint; Gabriel Delorme; David Attias; Florence Tubach; Sophie Dupuis-Girod; Henry Plauchu; Martine Barthelet; Francois Sassolas; Nicolas Pangaud; Sophie Naudion; Julie Thomas-Chabaneix; Yves Dulac; Thomas Edouard; Jean-Eric Wolf; Laurence Faivre; Sylvie Odent; Adeline Basquin; Gilbert Habib; Patrick Collignon; Catherine Boileau; Guillaume Jondeau
Journal:  Eur Heart J       Date:  2015-05-02       Impact factor: 29.983

4.  Revised diagnostic criteria for the Marfan syndrome.

Authors:  A De Paepe; R B Devereux; H C Dietz; R C Hennekam; R E Pyeritz
Journal:  Am J Med Genet       Date:  1996-04-24

5.  Atenolol versus losartan in children and young adults with Marfan's syndrome.

Authors:  Ronald V Lacro; Harry C Dietz; Lynn A Sleeper; Anji T Yetman; Timothy J Bradley; Steven D Colan; Gail D Pearson; E Seda Selamet Tierney; Jami C Levine; Andrew M Atz; D Woodrow Benson; Alan C Braverman; Shan Chen; Julie De Backer; Bruce D Gelb; Paul D Grossfeld; Gloria L Klein; Wyman W Lai; Aimee Liou; Bart L Loeys; Larry W Markham; Aaron K Olson; Stephen M Paridon; Victoria L Pemberton; Mary Ella Pierpont; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; Angela M Sharkey; Mario P Stylianou; Stephanie Burns Wechsler; Luciana T Young; Lynn Mahony
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

6.  Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome.

Authors:  M A Salim; B S Alpert; J C Ward; R E Pyeritz
Journal:  Am J Cardiol       Date:  1994-09-15       Impact factor: 2.778

7.  Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome.

Authors:  Romy Franken; Alexander W den Hartog; Teodora Radonic; Dimitra Micha; Alessandra Maugeri; Fleur S van Dijk; Hanne E Meijers-Heijboer; Janneke Timmermans; Arthur J Scholte; Maarten P van den Berg; Maarten Groenink; Barbara J M Mulder; Aeilko H Zwinderman; Vivian de Waard; Gerard Pals
Journal:  Circ Cardiovasc Genet       Date:  2015-01-22

8.  Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.

Authors:  Alex Pitcher; Jonathan Emberson; Ronald V Lacro; Lynn A Sleeper; Mario Stylianou; Lynn Mahony; Gail D Pearson; Maarten Groenink; Barbara J Mulder; Aeilko H Zwinderman; Julie De Backer; Anne M De Paepe; Eloisa Arbustini; Guliz Erdem; Xu Yu Jin; Marcus D Flather; Michael J Mullen; Anne H Child; Alberto Forteza; Arturo Evangelista; Hsin-Hui Chiu; Mei-Hwan Wu; George Sandor; Ami B Bhatt; Mark A Creager; Richard B Devereux; Bart Loeys; J Colin Forfar; Stefan Neubauer; Hugh Watkins; Catherine Boileau; Guillaume Jondeau; Harry C Dietz; Colin Baigent
Journal:  Am Heart J       Date:  2015-02-12       Impact factor: 4.749

9.  A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.

Authors:  Michael J Mullen; Marcus D Flather; Xu Yu Jin; William G Newman; Guliz Erdem; David Gaze; Oswaldo Valencia; Winston Banya; Claire E Foley; Anne Child
Journal:  Trials       Date:  2013-12-01       Impact factor: 2.279

10.  Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.

Authors:  Stijntje Hibender; Romy Franken; Cindy van Roomen; Anique Ter Braake; Ingeborg van der Made; Edith E Schermer; Quinn Gunst; Maurice J van den Hoff; Esther Lutgens; Yigal M Pinto; Maarten Groenink; Aeilko H Zwinderman; Barbara J M Mulder; Carlie J M de Vries; Vivian de Waard
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-06-09       Impact factor: 8.311
View more
  1 in total

1.  Successful repair of a popliteal aneurysm with saphenous vein graft in a patient with Marfan syndrome.

Authors:  Kate Xin Peng; Victor J Davila; Richard J Fowl
Journal:  J Vasc Surg Cases Innov Tech       Date:  2019-09-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.